Research programme: TLR4/MD-2 complex formation inhibitors - BiolineRx/University of Colorado-Boulder

Drug Profile

Research programme: TLR4/MD-2 complex formation inhibitors - BiolineRx/University of Colorado-Boulder

Alternative Names: BL-1110; EDP-34

Latest Information Update: 27 Jun 2014

Price : $50

At a glance

  • Originator University of Colorado at Boulder
  • Developer BioLineRx; University of Colorado at Boulder
  • Class Small molecules
  • Mechanism of Action Membrane protein inhibitors; Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuropathic pain
  • Research Scleroderma

Most Recent Events

  • 23 Jun 2014 Preclinical trials in Neuropathic pain in Israel (PO)
  • 23 Jun 2014 Preclinical trials in Neuropathic pain in USA (PO)
  • 23 Jun 2014 BL 1110 in-licensed by BiolineRx from the University of Colorado at Boulder in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top